Literature DB >> 6391989

Insulin and glucagon in spontaneously diabetic non-obese mice.

A Ohneda, T Kobayashi, J Nihei, Y Tochino, H Kanaya, S Makino.   

Abstract

To investigate the role of glucagon in the development of diabetes mellitus, spontaneously diabetic non-obese mice were studied before (group 1) and after the onset of diabetes mellitus (group 2). In group 1, fasting blood glucose and insulin in plasma and pancreas did not differ significantly, while plasma glucagon was elevated (48.9 +/- 10.4 versus control 18.6 +/- 6.0 pmol/l). In group 2, the insulin content of plasma and the pancreas were markedly reduced, whereas plasma glucagon was elevated (180.9 +/- 59.1 pmol/l). When diabetic mice were treated with insulin for 4 weeks (group 3), plasma glucagon was markedly reduced compared with that of group 2 (30.3 +/- 9.0 pmol/l). In group 1, glucagon and glucagon-like immunoreactivity of the intestine were reduced. The glucagon content of the intestine was elevated in group 2. Group 3 elicited increased contents of gastric glucagon as well as intestinal glucagon-like immunoreactivity. We conclude that, in addition to insulin deficiency, hypersecretion of glucagon might contribute to the development and clinical course of diabetes mellitus in the non-obese diabetic mouse.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6391989     DOI: 10.1007/BF00273911

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Extractable glucagon of the human pancreas.

Authors:  A J KENNY
Journal:  J Clin Endocrinol Metab       Date:  1955-09       Impact factor: 5.958

2.  The spontaneously diabetic Wistar rat (the "BB" rat). Studies prior to and during development of the overt syndrome.

Authors:  A F Nakhooda; A A Like; C I Chappel; C N Wei; E B Marliss
Journal:  Diabetologia       Date:  1978-03       Impact factor: 10.122

3.  Increased "glucagon immunoreactivity" in plasma of totally depancreatized dogs.

Authors:  M Vranic; S Pek; R Kawamori
Journal:  Diabetes       Date:  1974-11       Impact factor: 9.461

4.  Glucagon response to arginine after treatment of diabetes mellitus.

Authors:  A Ohneda; S Ishii; K Horigome; S Yamagata
Journal:  Diabetes       Date:  1975-09       Impact factor: 9.461

5.  The spontaneously diabetic Wistar rat. Metabolic and morphologic studies.

Authors:  A F Nakhooda; A A Like; C I Chappel; F T Murray; E B Marliss
Journal:  Diabetes       Date:  1977-02       Impact factor: 9.461

6.  Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity.

Authors:  S Kataoka; J Satoh; H Fujiya; T Toyota; R Suzuki; K Itoh; K Kumagai
Journal:  Diabetes       Date:  1983-03       Impact factor: 9.461

7.  Glucagon and insulin relationships in genetically diabetic (db/db) and in streptozotocin-induced diabetic mice.

Authors:  S B Stearns; C A Benzo
Journal:  Horm Metab Res       Date:  1978-01       Impact factor: 2.936

8.  Glucagon in spontaneously diabetic KK mice.

Authors:  A Ohneda; T Kobayashi; J Nihei; K Nishikawa
Journal:  Horm Metab Res       Date:  1981-04       Impact factor: 2.936

9.  Elevated portal and peripheral blood concentration of immunoreactive somatostatin in spontaneously diabetic (BBL) Wistar rats: suppression with insulin.

Authors:  Y C Patel; T Wheatley; F Malaisse-Lagae; L Orci
Journal:  Diabetes       Date:  1980-09       Impact factor: 9.461

10.  A new mutation (db3J) at the diabetes locus in strain 129/J mice. I. Physiological and histological characterization.

Authors:  E H Leiter; D L Coleman; A B Eisenstein; I Strack
Journal:  Diabetologia       Date:  1980-07       Impact factor: 10.122

View more
  10 in total

1.  Diabetes increases the expression of hypothalamic neuropeptides in a spontaneous model of type I diabetes, the nonobese diabetic (NOD) mouse.

Authors:  F E Saravia; S L Gonzalez; P Roig; V Alves; F Homo-Delarche; A F De Nicola
Journal:  Cell Mol Neurobiol       Date:  2001-02       Impact factor: 5.046

Review 2.  Type 1 diabetes in mice and men: gene expression profiling to investigate disease pathogenesis.

Authors:  Linda Yip; C Garrison Fathman
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

3.  The non-obese diabetic (NOD) mouse.

Authors:  E H Leiter; M Prochazka; D L Coleman
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

4.  Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus.

Authors:  E Strandell; D L Eizirik; S Sandler
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  Atrial natriuretic hormone prohormone gene expression in cardiac and extra-cardiac tissues of diabetic Goto-Kakizaki rats.

Authors:  William R Gower; Gloria I San Miguel; Gay M Carter; Imran Hassan; Robert V Farese; David L Vesely
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

6.  Atrial natriuretic peptide (ANP): a study of ANP and its mRNA in cardiocytes, and of plasma ANP levels in non-obese diabetic mice.

Authors:  H Mifune; S Suzuki; J Honda; Y Kobayashi; Y Noda; Y Hayashi; K Mochizuki
Journal:  Cell Tissue Res       Date:  1992-02       Impact factor: 5.249

7.  Bone marrow transplantation reverses new-onset immunoinflammatory diabetes in a mouse model.

Authors:  Cheng-Lan Lv; Jing Wang; Ting Xie; Jian Ouyang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

Review 8.  Lessons from the NOD mouse for the pathogenesis and immunotherapy of human type 1 (insulin-dependent) diabetes mellitus.

Authors:  E F Lampeter; A Signore; E A Gale; P Pozzilli
Journal:  Diabetologia       Date:  1989-10       Impact factor: 10.122

9.  Diminished adenosine A1 receptor expression in pancreatic α-cells may contribute to the pathology of type 1 diabetes.

Authors:  Linda Yip; Cariel Taylor; Chan C Whiting; C Garrison Fathman
Journal:  Diabetes       Date:  2013-12       Impact factor: 9.461

10.  Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells.

Authors:  A Bendelac; C Carnaud; C Boitard; J F Bach
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.